Evidence map›Paper›PMID 29532998›Full record

ArticleCancer medicine2018

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR

Zhang Zhang, Jian Zou, Lei Yu, Jinfeng Luo, Yan Li, Zhengchao Tu, Xiaomei Ren, Hongcheng Wei, Liyan Song, Xiaoyun Lu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhang ZhangSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Jian ZouSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Lei YuUniversity of Chinese Academy of Sciences, 19 Yuquan Road, Beijing, 100049, China.
Jinfeng LuoGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, China.
Yan LiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Zhengchao TuGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, China.
Xiaomei RenSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Hongcheng WeiThe First Affiliated Hospital, Jinan University, 613 Huangpu Avenue West, Guangzhou, 510630, China.
Liyan SongSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Xiaoyun LuSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.
Ke DingSchool of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.ORCID 0000-0001-9016-812X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

YL143 was identified as a novel wild-type sparing EGFR

Indexed as

AllelesAmino Acid SubstitutionMutationAnimalsAntineoplastic AgentsCell CycleCell Line, TumorCell ProliferationDisease Models, AnimalDrug Resistance, NeoplasmErbB ReceptorsHumansMaleMiceMolecular ConformationMolecular Docking SimulationAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsEGFR inhibitorlung cancerpharmacokineticselectivelyT790M mutation

Identifiers

PMID29532998
PMCPMC5911580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.